IVERIC bio Revenue and Competitors

Location

#2557

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • IVERIC bio's estimated annual revenue is currently $19.1M per year.(i)
  • IVERIC bio's estimated revenue per employee is $67,130
  • IVERIC bio's total funding is $382.9M.
  • IVERIC bio's current valuation is $1.6B. (January 2022)

Employee Data

  • IVERIC bio has 284 Employees.(i)
  • IVERIC bio grew their employee count by 52% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M7250%N/AN/A
#2
$5.9M3815%N/AN/A
#3
$34.7M2246%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.9M6-14%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$4.2M27-16%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

IVERIC bio is a gene therapy focused company developing innovative treatments for patients with orphan inherited retinal diseases with significant unmet medical needs. We have a diversified and scientifically compelling pipeline of product candidates. At IVERIC bio we understand the critical importance of vision in the quality of life of patients.

keywords:N/A

$382.9M

Total Funding

284

Number of Employees

$19.1M

Revenue (est)

52%

Employee Growth %

$1.6B

Valuation

N/A

Accelerator

IVERIC bio News

2022-04-20 - IVERIC bio, Inc. (NASDAQ:ISEE) Receives Average ...

IVERIC bio, Inc. (NASDAQ:ISEE – Get Rating) has received a consensus recommendation of “Buy” from the eight research firms that are...

2022-04-19 - -$0.29 EPS Expected for IVERIC bio, Inc. (NASDAQ:ISEE ...

IVERIC bio also reported earnings of ($0.29) per share during the same quarter last year. The business is scheduled to issue its next earnings...

2022-04-06 - Should You Buy IVERIC bio Inc (ISEE) Stock on Tuesday?

IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$39.7M2844%$100.9M
#2
$64M2848%N/A
#3
$56.2M284N/AN/A
#4
$64M2840%N/A
#5
$50M28425%N/A